Linda Baddour
Known title: DirectorCIK: 0001181151
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Waters Launches AI Link for LC-MS Workflows. Waters Corporation introduced AI Link, a tool designed to advance AI-enabled LC-MS workflows from research to release. This product launch highlights the company's focus on integrating artificial intelligence into its laboratory solutions. Additionally, TD Cowen raised its price target to $515, reflecting continued analyst interest in the stock's potential.
Transaction History
| CYRX | ▲ Buy | Grant | 10,350 | $0 | 6/5/2026 | View on chart |
| WAT | ▲ Buy | Grant | 23 | $0 | 2/25/2026 | View on chart |
| WAT | ▲ Buy | Grant | 307 | $0 | 1/2/2026 | View on chart |
| CYRX | ▲ Buy | Grant | 23,214 | $0 | 6/6/2025 | View on chart |
| WAT | ▲ Buy | Grant | 319 | $0 | 1/2/2025 | View on chart |
| CYRX | ▲ Buy | Grant | 12,845 | $0 | 5/17/2024 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 1,111 | $0 | 3/15/2024 | View on chart |
| WAT | ▼ Sell | Open Market | 500 | $178K | 3/13/2024 | View on chart |
| WAT | ▲ Buy | Grant | 334 | $0 | 1/2/2024 | View on chart |
| CYRX | ▲ Buy | Grant | 8,105 | $0 | 5/12/2023 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 1,111 | $0 | 3/15/2023 | View on chart |
| WAT | ▲ Buy | Grant | 318 | $0 | 1/3/2023 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 2,708 | — | 4/30/2022 | View on chart |
| CYRX | ▲ Buy | Grant | 7,203 | $0 | 4/29/2022 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 1,111 | $0 | 3/15/2022 | View on chart |
| WAT | ▲ Buy | Grant | 301 | $110K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
BTIG Keeps CryoPort Target at $25 Amid Cell Therapy Pipeline
BTIG reiterated its positive stance on CryoPort, maintaining a $25 price target. This follows commentary highlighting the company's strong pipeline of cell and gene therapy approvals. The stock is currently trading near the upper end of its 52-week range, reflecting recent momentum in the sector.
BTIG Keeps CryoPort Target at $25 Amid Cell Therapy Pipeline. BTIG reiterated its positive stance on CryoPort, maintaining a $25 price target. This follows commentary highlighting the company's strong pipeline of cell and gene therapy approvals. The stock is currently trading near the upper end of its 52-week range, reflecting recent momentum in the sector.